clinical trial · NCT07669571
A Phase I Study of NS-079 in Healthy Participants
NeuShen Therapeutics·phase1·recruiting·n = 78
Healthy Adult ParticipantsPlaceboNS-079 tabletParoxetine
brief summary
The goal of this clinical trial is evaluate the safety, pharmacokinetics, and pharmacodynamics of NS-079 with its main metabolite (NS-079-M1) in healthy participants. The main questions it aims to answer are: * Is NS-079 safe and tolerable in heathy participants under tested dosing regimen? * What is the pharmacokinectic profile of NS-079 in healthy participants under tested dosing regimen and the effect of paroxetine? Researchers will compare NS-079 to a placebo to see the safety and tolerability when use NS-079.
started
Jul 30, 2026
primary completion
Feb 28, 2027
completion
Feb 28, 2027
last updated
Sep 15, 2026
official title
A Phase I, Double-blind, Placebo-controlled Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of NS-079 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol